{"id":18287,"date":"2022-01-03T10:29:05","date_gmt":"2022-01-03T18:29:05","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18287"},"modified":"2022-01-03T10:29:06","modified_gmt":"2022-01-03T18:29:06","slug":"fda-grants-rpd-to-immix-biopharma","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/","title":{"rendered":"FDA Grants RPD to Immix Biopharma"},"content":{"rendered":"\n

Immix Biopharma, Inc. (Nasdaq: IMMX) announced <\/a>earlier today the U.S. Food and Drug Administration\u2019s decision to grant a Rare Pediatric Disease (RPD) designation for the company’s IMX-110 as a treatment for life-threatening pediatric cancer in children.<\/p>\n\n\n\n

Urgent Application<\/h5>\n\n\n\n

IMX-110 is currently being evaluated in a Phase 1b\/2a clinical trial and should the company’s\u00a0New Drug Application in the United States for IMX-110 be approved, ImmixBio may be eligible to receive a Priority Review Voucher, granting it the ability to obtain priority review for any subsequent marketing application.<\/p>\n\n\n\n

\u201cWe are pleased by FDA\u2019s acknowledgment of the urgent need for a safe and effective treatment for children with this devastating disease.\u201d<\/p>ImmixBio\u2019s Chief Executive Officer Ilya Rachman, M.D., PhD<\/cite><\/blockquote>\n\n\n\n

Additionally, IMX-110 has already been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of soft tissue sarcoma, and is the first clinical-stage product of ImmixBio\u2019s SMARxT Tissue-Specific\u2122 Platform.\u00a0<\/p>\n\n\n\n

\u201cWe are encouraged by our Phase 1b\/2a clinical data in soft tissue sarcoma. IMX-110 is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment, severing the critical lifelines between the tumor and its metabolic and structural support. We believe our SMARxT platform generating Tissue-Specific Therapeutics represents a distinct alternative to the traditional \u2018single target, single mutation\u2019 development model.\u201d<\/p>ImmixBio\u2019s Chief Executive Officer Ilya Rachman, M.D., PhD<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Immix Biopharma, Inc. (Nasdaq: IMMX) announced earlier today the U.S. Food and Drug Administration\u2019s decision to grant a Rare Pediatric Disease (RPD) designation for the company’s IMX-110 as a treatment for life-threatening pediatric cancer in children. Urgent Application IMX-110 is currently being evaluated in a Phase 1b\/2a clinical trial and should the company’s\u00a0New Drug Application… View Article<\/a>","protected":false},"author":3,"featured_media":17705,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nFDA Grants RPD to Immix Biopharma - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Grants RPD to Immix Biopharma - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"Immix Biopharma, Inc. (Nasdaq: IMMX) announced earlier today the U.S. Food and Drug Administration\u2019s decision to grant a Rare Pediatric Disease (RPD) designation for the company’s IMX-110 as a treatment for life-threatening pediatric cancer in children. Urgent Application IMX-110 is currently being evaluated in a Phase 1b\/2a clinical trial and should the company’s\u00a0New Drug Application... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-03T18:29:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-03T18:29:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/10\/VivosTherapeuticsFDAApproval.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"FDA Grants RPD to Immix Biopharma\",\"datePublished\":\"2022-01-03T18:29:05+00:00\",\"dateModified\":\"2022-01-03T18:29:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\"},\"wordCount\":234,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\",\"url\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\",\"name\":\"FDA Grants RPD to Immix Biopharma - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-01-03T18:29:05+00:00\",\"dateModified\":\"2022-01-03T18:29:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Grants RPD to Immix Biopharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Grants RPD to Immix Biopharma - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/","og_locale":"en_US","og_type":"article","og_title":"FDA Grants RPD to Immix Biopharma - MarketDepth","og_description":"Immix Biopharma, Inc. (Nasdaq: IMMX) announced earlier today the U.S. Food and Drug Administration\u2019s decision to grant a Rare Pediatric Disease (RPD) designation for the company’s IMX-110 as a treatment for life-threatening pediatric cancer in children. Urgent Application IMX-110 is currently being evaluated in a Phase 1b\/2a clinical trial and should the company’s\u00a0New Drug Application... View Article","og_url":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-01-03T18:29:05+00:00","article_modified_time":"2022-01-03T18:29:06+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/10\/VivosTherapeuticsFDAApproval.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"FDA Grants RPD to Immix Biopharma","datePublished":"2022-01-03T18:29:05+00:00","dateModified":"2022-01-03T18:29:06+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/"},"wordCount":234,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/","url":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/","name":"FDA Grants RPD to Immix Biopharma - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-01-03T18:29:05+00:00","dateModified":"2022-01-03T18:29:06+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/fda-grants-rpd-to-immix-biopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"FDA Grants RPD to Immix Biopharma"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18287"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=18287"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18287\/revisions"}],"predecessor-version":[{"id":18288,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18287\/revisions\/18288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/17705"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=18287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=18287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=18287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}